Zhongze Completes China Dose Escalation Trial for Schizophrenia Therapy

Shanghai Zhongze Therapeutics successfully completed a China Phase I dose escalating study in healthy volunteers of its self-developed therapy for schizophrenia. ZZ6398 is the first pan-antagonist of D₂, D₃, 5-HT_1A and 5-HT_2A receptors designed to treat cognitive impairment associated with schizophrenia by fine-tuning the D₂/D₃ selectivity and 5-HT_1A antagonism. Zhongze reported the candidate was well tolerated with a better-than-expected PK profile. The company develops neurological and psychiatric products for unmet needs, with one in-licensed product and two clinical stage CNS candidates and three molecules in pre-clinical development. More details....

Share this with colleagues: